Phase II Clinical Study Of Elenbecestat Demonstrates Safety And Tolerability In MCI And Mild To Moderate Alzheimer’s Disease At 18-Months

Great Lakes Clinical Trials is pleased to share this press release in regards to a Alzheimer's disease research program in which we are participating.  If you are interested in learning how to participate, please click HERE for more information.

June 5, 2018
Eisai Co., Ltd. (
Biogen Inc. (

Results Of The Phase II Study Demonstrated A Statistically Significant Difference In Amyloid Beta In Brain

 Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”) announced today that elenbecestat was generally safe and well tolerated in a Phase II clinical study (Study 202) of the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) conducted in the United States, and the results demonstrated a statistically significant difference in amyloid beta (Aβ) levels in the brain measured by amyloid-PET (positron emission tomography). A numerical slowing of decline in functional clinical scales of a potentially clinically important difference was also observed, although this effect was not statistically significant. This study, a Phase II study of 70 patients, is the first study of a BACE inhibitor to show a statistically significant difference in amyloid beta in the brain while also suggesting a delay of clinical symptom decline in exploratory endpoints. 

To download a full version of the press release, click HERE.
You can also view it directly on Biogen's website by clicking HERE or on Eisai's website by clicking HERE